Drug profile

The FDA adverse-event record for Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol

59 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol. See the species affected, top reactions, and outcomes below.

59
adverse-event reports
86.4%
death-coded share
Cattle
most-reported species
52
Lack of efficacy (bacteria) - NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
59
Total Reports
51
Deaths Reported
86.4%
Death Rate

Active Ingredients

Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol

Administration Routes

Subcutaneous

Species Affected

Cattle 59

Most Affected Breeds

Cattle (other) 40
Crossbred Bovine/Cattle 7
Aberdeen Angus 4
Cattle (unknown) 2
Holstein-Friesian also known as Holstein 2
Mixed (Cattle) 2
Cattle (unspecified) 1
Charolais 1

Most Reported Reactions

Lack of efficacy (bacteria) - NOS 52
Death 38
Lack of efficacy - NOS 10
CULTURE/TITER DATA ABNORMAL 9
Increased mortality rate 6
Abnormal test result 5
DEATH-TREATMENT FAILURE 4
Death by euthanasia 3
Lack of efficacy (protozoa) - Coccidia 3
PR-LUNG(S), LESION(S) 3
Fever 3
Pneumonia 2

Outcome Breakdown

Died
50 (47.2%)
Outcome Unknown
36 (34.0%)
Recovered/Normal
9 (8.5%)
Ongoing
7 (6.6%)
Euthanized
2 (1.9%)
Recovered with Sequela
2 (1.9%)

Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol Adverse Event Insights

59 reports name Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol; 51 recorded a death outcome (86.4% of reported events, not a population-level mortality rate). Active ingredient: Mannheimia Haemolytica Type A1, Nl-1009, Capsular Antigen, Kb; Mannheimia Haemol. Administration route: Subcutaneous.

By species: Cattle (59 reports). By breed: Cattle (other) (40), Crossbred Bovine/Cattle (7), Aberdeen Angus (4).

Leading clinical signs: Lack of efficacy (bacteria) - NOS (52), Death (38), Lack of efficacy - NOS (10), CULTURE/TITER DATA ABNORMAL (9). Outcome, 106 coded reports: Died leads at 47.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.